Marty Makary resigned as U.S. FDA commissioner, with Kyle Diamantas stepping in as acting commissioner. The leadership change follows a period of internal turnover and industry concern about the predictability of review timelines and guidance, according to multiple reports. For biotech, the immediate impact is uncertainty around how the agency will manage ongoing drug-development reforms, including expedited pathways and AI-adjacent review efforts. With senior drug-review roles operating in an “acting” capacity subject to time limits, observers expect additional personnel movement. The transition raises the risk of operational disruption during a window when sponsors are already coordinating pivotal trial planning and submission timelines around FDA expectations.